BRPI0508557A - composição farmacêutica que compreende pimobendan - Google Patents

composição farmacêutica que compreende pimobendan

Info

Publication number
BRPI0508557A
BRPI0508557A BRPI0508557-8A BRPI0508557A BRPI0508557A BR PI0508557 A BRPI0508557 A BR PI0508557A BR PI0508557 A BRPI0508557 A BR PI0508557A BR PI0508557 A BRPI0508557 A BR PI0508557A
Authority
BR
Brazil
Prior art keywords
pimobendan
pharmaceutical composition
solid formulations
relates
medicament
Prior art date
Application number
BRPI0508557-8A
Other languages
English (en)
Inventor
Martin Andreas Folger
Bernhard Hassel
Stefan Henke
Jens Schmalz
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34877563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508557(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of BRPI0508557A publication Critical patent/BRPI0508557A/pt
Publication of BRPI0508557B1 publication Critical patent/BRPI0508557B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

COMPOSIçãO FARMACêUTICA QUE COMPREENDE PIMOBENDAN. A presente invenção refere-se a novas formulações sólidas que compreendem como o composto farmaceuticamente ativo o pimobendan e aos processos para a produção de tais formulações sólidas. A invenção, além disso, se refere a um método para a produção de um medicamento para a prevenção e/ou para o tratamento da falência cardíaca congestiva, em que são utilizadas as formulações sólidas de acordo com a invenção.
BRPI0508557A 2004-03-08 2005-03-01 "formulação sólida que compreende pimobendan, processos de granulação em leito fluidizado e produção de medicamento e kit compreendendo a referida formulação". BRPI0508557B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004011512.5A DE102004011512B4 (de) 2004-03-08 2004-03-08 Pharmazeutische Zubereitung enthaltend Pimobendan
PCT/EP2005/002133 WO2005084647A1 (en) 2004-03-08 2005-03-01 Pharmaceutical composition comprising pimobendan

Publications (2)

Publication Number Publication Date
BRPI0508557A true BRPI0508557A (pt) 2007-08-07
BRPI0508557B1 BRPI0508557B1 (pt) 2018-12-18

Family

ID=34877563

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508557A BRPI0508557B1 (pt) 2004-03-08 2005-03-01 "formulação sólida que compreende pimobendan, processos de granulação em leito fluidizado e produção de medicamento e kit compreendendo a referida formulação".

Country Status (25)

Country Link
US (5) US8846679B2 (pt)
EP (2) EP1725218B1 (pt)
JP (2) JP4757253B2 (pt)
KR (2) KR20070014143A (pt)
CN (1) CN100546568C (pt)
AR (2) AR047993A1 (pt)
AU (1) AU2005218912C1 (pt)
BR (1) BRPI0508557B1 (pt)
CA (1) CA2557161C (pt)
CY (2) CY1115526T1 (pt)
DE (1) DE102004011512B4 (pt)
DK (2) DK1725218T3 (pt)
ES (2) ES2736022T3 (pt)
HR (2) HRP20140900T1 (pt)
HU (1) HUE045637T2 (pt)
IN (1) IN2014DN07624A (pt)
LT (1) LT2783682T (pt)
MX (1) MXPA06009889A (pt)
NZ (1) NZ549630A (pt)
PL (2) PL1725218T3 (pt)
PT (2) PT1725218E (pt)
SI (2) SI1725218T1 (pt)
TW (1) TWI355947B (pt)
WO (1) WO2005084647A1 (pt)
ZA (1) ZA200606154B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP4572293B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
JP2006028130A (ja) * 2004-07-21 2006-02-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP4572296B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
JP4572300B2 (ja) * 2006-01-19 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
WO2010055119A2 (en) * 2008-11-17 2010-05-20 Novartis Ag Pharmaceutical composition comprising pimobendan
KR20110089851A (ko) 2008-11-25 2011-08-09 베링거잉겔하임베트메디카게엠베하 비대 심근병증의 치료를 위한 포스포디에스테라제 타입 Ⅲ（ＰＤＥ Ⅲ） 억제제 또는 Ｃａ２＋―감작제
NL1037569C2 (en) 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
MX365621B (es) 2011-12-21 2019-06-07 Elanco Tiergesundheit Ag Nueva combinacion.
WO2013135853A1 (en) * 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical packaging product for the veterinary medical sector
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
UA118748C2 (uk) * 2012-12-19 2019-03-11 Байєр Енімал Хелс Гмбх Таблетки, що мають покращене сприйняття та хорошу стабільність при зберіганні
KR102455648B1 (ko) 2013-07-19 2022-10-19 베링거잉겔하임베트메디카게엠베하 보존된 에테르화된 사이클로덱스트린 유도체 함유 액체 수성 약제학적 조성물
BR112016011111B1 (pt) * 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US11246867B2 (en) 2015-12-17 2022-02-15 Ceva Sante Animale Pharmaceutical composition comprising pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN106729723A (zh) * 2016-11-21 2017-05-31 青岛农业大学 一种含匹莫苯丹的药物组合物及其制备方法
KR102116712B1 (ko) * 2017-12-22 2020-05-29 주식회사 고려비엔피 기호성이 증진된 경구 투여 제제를 포함하는 개과 동물의 이첨판 판막 변성증 치료 또는 증상 완화용 제제
CN114599353A (zh) * 2019-10-23 2022-06-07 皮埃蒙特动物健康公司 匹莫苯制剂及其使用方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
JPS5636911A (en) * 1979-09-05 1981-04-10 Aisin Seiki Mechanism for adjusting headrest
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
ZA878182B (en) 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3728244A1 (de) 1987-08-25 1989-03-09 Thomae Gmbh Dr K Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de) 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de) 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
IE62095B1 (en) 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
DE68906942T3 (de) 1988-03-29 1999-05-12 Univ Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
DE4001622A1 (de) 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
DE4001623A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen geeigneten arzneimittels
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH0570612A (ja) 1991-09-12 1993-03-23 Toyobo Co Ltd 二軸配向ポリエステルフイルム
CZ290406B6 (cs) * 1994-05-20 2002-07-17 Janssen Pharmaceutica N. V. Anthelmintický prostředek a jeho pouľití
JPH11228302A (ja) 1998-02-18 1999-08-24 Taisho Technos Co Ltd 抗菌防黴組成物
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
KR100784752B1 (ko) 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물
US7727548B2 (en) 2000-03-01 2010-06-01 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
WO2001097861A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7744855B2 (en) * 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2002049645A1 (en) 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril
EP1247456A3 (en) * 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
HUP0303484A2 (hu) 2001-03-02 2004-01-28 Bristol-Myers Squibb Company Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények
AU2002312543A1 (en) 2001-08-01 2003-02-17 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
MXPA04010951A (es) 2002-05-23 2005-06-08 Pfizer Nueva combinacion.
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
RU2005110062A (ru) 2002-10-07 2006-01-10 Артезиан Терапьютикс, Инк. (US) Дигидропиридиновые соединения, обладающие одновременной способностью к блокированию кальциевых каналов l-типа и к ингибированию активности фосфодиэстеразы типа 3
EP1565472A2 (en) 2002-11-27 2005-08-24 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
JP2006513222A (ja) 2002-12-23 2006-04-20 アルテシアン セラピューティック，インコーポレイティド アドレナリン性β受容体およびホスホジエステラーゼに対する抑制活性を有する強心性化合物
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP2005281283A (ja) 2004-03-31 2005-10-13 Akira Matsumori ベンズイミダゾール系薬剤の併用医薬
FI20040675A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
NZ534939A (en) 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
JP2008521805A (ja) 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
WO2006060127A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
CN1702243A (zh) 2005-05-31 2005-11-30 刘坚雄 无壁板框架结构装配组合式房屋建筑及其建造方法
CA2611917A1 (en) 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
CA2629367C (en) 2005-11-14 2016-05-03 Boehringer Ingelheim Vetmedica Gmbh Use of pde iii inhibitors and/or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
KR20110089851A (ko) 2008-11-25 2011-08-09 베링거잉겔하임베트메디카게엠베하 비대 심근병증의 치료를 위한 포스포디에스테라제 타입 Ⅲ（ＰＤＥ Ⅲ） 억제제 또는 Ｃａ２＋―감작제

Also Published As

Publication number Publication date
US20170368062A1 (en) 2017-12-28
CA2557161A1 (en) 2005-09-15
TWI355947B (en) 2012-01-11
BRPI0508557B1 (pt) 2018-12-18
DE102004011512A1 (de) 2005-09-22
EP2783682A1 (en) 2014-10-01
AR106850A2 (es) 2018-02-21
EP1725218A1 (en) 2006-11-29
MXPA06009889A (es) 2007-11-20
PL1725218T3 (pl) 2014-11-28
ZA200606154B (en) 2007-11-28
JP5875231B2 (ja) 2016-03-02
SI2783682T1 (sl) 2019-08-30
DK2783682T3 (da) 2019-08-12
JP2007526269A (ja) 2007-09-13
NZ549630A (en) 2009-07-31
SI1725218T1 (sl) 2014-09-30
HRP20191360T1 (hr) 2019-11-01
CY1121877T1 (el) 2020-10-14
JP4757253B2 (ja) 2011-08-24
US20120148640A1 (en) 2012-06-14
HRP20140900T1 (hr) 2014-11-07
JP2011098977A (ja) 2011-05-19
US8859554B2 (en) 2014-10-14
US20130177613A1 (en) 2013-07-11
AU2005218912C1 (en) 2012-10-25
US20140363510A1 (en) 2014-12-11
CN100546568C (zh) 2009-10-07
TW200539901A (en) 2005-12-16
ES2501216T3 (es) 2014-10-01
PT2783682T (pt) 2019-09-10
AR047993A1 (es) 2006-03-15
LT2783682T (lt) 2019-07-25
AU2005218912A1 (en) 2005-09-15
ES2736022T3 (es) 2019-12-23
US20050203097A1 (en) 2005-09-15
AU2005218912B2 (en) 2010-09-16
CY1115526T1 (el) 2017-01-04
KR20120006089A (ko) 2012-01-17
CN1929821A (zh) 2007-03-14
EP2783682B1 (en) 2019-05-22
EP1725218B1 (en) 2014-06-25
US8846679B2 (en) 2014-09-30
IN2014DN07624A (pt) 2015-07-10
HUE045637T2 (hu) 2020-01-28
US8846680B2 (en) 2014-09-30
CA2557161C (en) 2013-06-25
DE102004011512B4 (de) 2022-01-13
KR20070014143A (ko) 2007-01-31
WO2005084647A1 (en) 2005-09-15
PT1725218E (pt) 2014-09-03
KR101290077B1 (ko) 2013-08-01
DK1725218T3 (da) 2014-09-01
PL2783682T3 (pl) 2019-11-29

Similar Documents

Publication Publication Date Title
BRPI0508557A (pt) composição farmacêutica que compreende pimobendan
NO20082709L (no) Kjemiske forbindelser
NO20073719L (no) Kjemiske forbindelser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20091683L (no) Kjemiske forbindelser
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
MX2009004699A (es) Compuestos de piridinona.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
WO2008033562A3 (en) Kinase inhibitor compounds
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
BRPI0511874A (pt) derivados da pirrolopiridina
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
MX2011012122A (es) Derivados de tiofeno.
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
AU2009282962A8 (en) Compounds as kinase inhibitors
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20083836L (no) N-hydroksyakrylamidforbindelser

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/12/2018, OBSERVADAS AS CONDICOES LEGAIS.